Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
AHOD2131 - A Randomized, Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and Stage II Classic Hodgkin Lymphoma
NCT Number:
NCT05675410
Phase:
III
Protocol Type:
Treatment
Age Group:
Both
Disease Sites:
Hodgkin's Lymphoma
Study Objectives:
To compare the PFS of a standard chemotherapy approach versus an IO therapy approach (brentuximab vedotin and nivolumab) in patients with newly diagnosed early stage cHL who have a rapid early response (RER) as determined by PET2 after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy.
To compare the PFS of a standard chemotherapy approach versus an IO therapy approach (brentuximab vedotin and nivolumab) plus involved site radiation therapy (ISRT) in patients with newly diagnosed early stage cHL who have a slow early response (SER) as determined by PET2 after 2 cycles of ABVD chemotherapy.
Study Documents
(MUSC NetID required for document access)